|
Q3 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
Q3 FY2021
As of Jun 30, 2021
|
Q2 FY2021
As of Mar 31, 2021
|
Q1 FY2021
As of Dec 31, 2020
|
Q4 FY2020
As of Sep 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Available-for-sale securities | ||||||||||||||||||||
| Accounts receivable, net of allowances of $143 and $144 as of June 30, 2025 and September 30, 2024, respectively | ||||||||||||||||||||
| Contract assets | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Income tax receivable | ||||||||||||||||||||
| Prepaids and other | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Compensation | ||||||||||||||||||||
| Accrued other | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Income tax payable | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Long-term debt, net | ||||||||||||||||||||
| Deferred revenue, less current portion | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Common stock - $.05 par value, 45,000 shares authorized; 14,298 and 14,325 shares issued and outstanding as of June 30, 2025 and September 30, 2024, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total Stockholders’ Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity | ||||||||||||||||||||
Loading...
